Contributions
Abstract: PB1792
Type: Publication Only
Session title: Stem cell transplantation - Clinical
Background
In allogeneic transplantation the usual approach is to synchronize the conditioning of the patient with stem cell harvesting in order to infuse fresh cell products. The EBMT COVID-19 guidelines recommend cryopreservation of the graft to be considered if there is a concern that the donor is at risk of infection after the patient’s conditioning is initiated.
Aims
We analyzed if cell viability or hematological recovery is affected in case stem cells are previously frozen.
Methods
Results from two groups of patients, each comprising of 16 males and 8 females, were analyzed. HSC from the first group were non-programmed frozen and stored at −80ºC in a cryoprotective solution with a final 5% DMSO, 3.6% hydroxyethyl amylopectin (HES, Mw 450 000 Da) and 3% human serum albumin (HSA) concentrations. Platelets and plasma were removed from stem cell harvest prior to the addition of the cryoprotectant. The HSCs from the second group were transplanted without freezing. Fresh cell viability or viability after thawing (trypan blue exclusion test) and hematological recovery (neutrophils and platelets) of patients receiving cryopreserved cells or fresh cells were analyzed.
Results
The average viability was 98,67 % (SD ±1,633) for fresh HSCs and 91,63% (SD ±8,021) for cryopreserved cells. The average time for hematological recovery for the neutrophils, was 17,96(SD ±4,601) for fresh cells and 16,46 (SD ± 4,530 ) for frozen cells. The average time for hematological recovery for the platelets, was 15,25 (SD ± 4,590) for fresh cells and 16,26 (SD ± 6,032) for frozen cells. There was no statistically significant difference between the two groups for hematological recovery.
Conclusion
Use of fresh HSCs is the first choice for allogeneic stem cell transplantation. In cases of pandemics, such as the Covid-19 one, use of cells harvested and frozen prior to initiation of the condioning regimen is preferred. Cryopreservation of HSCs with a cryoprotective solution with low (5%) DMSO concentration and extracellular agents (hydroxyethyl amylopectin and HSA) is safe and well tolerated and gives excellent post thaw viability and post-transplant hematological recovery results.
Keyword(s): Cryopreservation, Stem cell transplant
Abstract: PB1792
Type: Publication Only
Session title: Stem cell transplantation - Clinical
Background
In allogeneic transplantation the usual approach is to synchronize the conditioning of the patient with stem cell harvesting in order to infuse fresh cell products. The EBMT COVID-19 guidelines recommend cryopreservation of the graft to be considered if there is a concern that the donor is at risk of infection after the patient’s conditioning is initiated.
Aims
We analyzed if cell viability or hematological recovery is affected in case stem cells are previously frozen.
Methods
Results from two groups of patients, each comprising of 16 males and 8 females, were analyzed. HSC from the first group were non-programmed frozen and stored at −80ºC in a cryoprotective solution with a final 5% DMSO, 3.6% hydroxyethyl amylopectin (HES, Mw 450 000 Da) and 3% human serum albumin (HSA) concentrations. Platelets and plasma were removed from stem cell harvest prior to the addition of the cryoprotectant. The HSCs from the second group were transplanted without freezing. Fresh cell viability or viability after thawing (trypan blue exclusion test) and hematological recovery (neutrophils and platelets) of patients receiving cryopreserved cells or fresh cells were analyzed.
Results
The average viability was 98,67 % (SD ±1,633) for fresh HSCs and 91,63% (SD ±8,021) for cryopreserved cells. The average time for hematological recovery for the neutrophils, was 17,96(SD ±4,601) for fresh cells and 16,46 (SD ± 4,530 ) for frozen cells. The average time for hematological recovery for the platelets, was 15,25 (SD ± 4,590) for fresh cells and 16,26 (SD ± 6,032) for frozen cells. There was no statistically significant difference between the two groups for hematological recovery.
Conclusion
Use of fresh HSCs is the first choice for allogeneic stem cell transplantation. In cases of pandemics, such as the Covid-19 one, use of cells harvested and frozen prior to initiation of the condioning regimen is preferred. Cryopreservation of HSCs with a cryoprotective solution with low (5%) DMSO concentration and extracellular agents (hydroxyethyl amylopectin and HSA) is safe and well tolerated and gives excellent post thaw viability and post-transplant hematological recovery results.
Keyword(s): Cryopreservation, Stem cell transplant